The 90 kDa heat shock proteins are proving to be extraordinary cancer chemotherapeutic targets as evidenced by the fact that 26 clinical trials are currently in progress. Unfortunately, all of these trials are based upon the N-terminal inhibitor, geldanamycin, which has serious formulation difficulties and produces toxicity unrelated to Hsp90 inhibition by virtue of its redox-active and electrophilic quinone ring. Only one total synthesis of this molecule has been reported, and the overall yield was 0.017% after 43 steps, suggesting that the preparation of analogues would be difficult. More recently, Neckers and coworkers determined that Hsp90 contains a C-terminal ATP binding site that bound coumarin antibiotics competitively versus ATP. Like N-terminal inhibitors, inhibitors of the C-terminal binding domain also cause the degradation of Hsp90-dependent client proteins involved in tumor cell growth and proliferation. A major drawback of the coumarin antibiotics is that they bind weakly to Hsp90 (IC50 approximately 700 micromolar); however, they remain the most potent C-terminal inhibitors described in the literature. We have recently identified a compound that is 700-7000 x's more active than the coumarin antibiotic in collaboration with Len Neckers and Jeff Holzbeierlein. This molecule has been evaluated in several tumor cell lines and has potent activity against a wide range of Hsp90 client proteins. In an effort to increase the potency of our lead molecule, we have proposed to incorporate functionalities that exist in the nucleotide specific substrates onto our lead compound to afford additional interactions with the Hsp90 C-terminal binding site. In addition, we propose to evaluate our lead compound in murine xenograft models of prostate cancer. Finally, it is proposed that by compromising the Hsp90 protein folding machinery with low doses of our lead compound, or any improved analogue, it will provide an acceptable concentration of other clinically used anti-tumor agents to induce apoptosis without detrimental side effects. As a consequence of these studies, we believe we can provide a basis upon which new inhibitors of the Hsp90 protein folding process can be developed without the deleterious side effects of the geldanamycin derivatives that are currently plagued in clinical trials. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01CA120458-03
Application #
7406727
Study Section
Drug Discovery and Molecular Pharmacology Study Section (DMP)
Program Officer
Lees, Robert G
Project Start
2006-05-19
Project End
2009-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
3
Fiscal Year
2008
Total Cost
$248,188
Indirect Cost
Name
University of Kansas Lawrence
Department
Pharmacology
Type
Schools of Pharmacy
DUNS #
076248616
City
Lawrence
State
KS
Country
United States
Zip Code
66045
Kumar Mv, Vasantha; Ebna Noor, Radwan; Davis, Rachel E et al. (2018) Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain. Medchemcomm 9:1323-1331
Zhang, Xinyue; Li, Chengyuan; Fowler, Stephen C et al. (2018) Targeting Heat Shock Protein 70 to Ameliorate c-Jun Expression and Improve Demyelinating Neuropathy. ACS Chem Neurosci 9:381-390
Zhang, Zheng; You, Zhenyuan; Dobrowsky, Rick T et al. (2018) Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity. Bioorg Med Chem Lett 28:2701-2704
Khandelwal, Anuj; Kent, Caitlin N; Balch, Maurie et al. (2018) Structure-guided design of an Hsp90? N-terminal isoform-selective inhibitor. Nat Commun 9:425
Garg, Gaurav; Zhao, Huiping; Blagg, Brian S J (2017) Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Bioorg Med Chem 25:451-457
Byrd, Katherine M; Kent, Caitlin N; Blagg, Brian S J (2017) Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors. ChemMedChem 12:2022-2029
Davis, Rachel E; Zhang, Zheng; Blagg, Brian S J (2017) A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library. Medchemcomm 8:593-598
Forsberg, Leah K; Liu, Weiya; Holzbeierlein, Jeffrey et al. (2017) Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer. Bioorg Med Chem Lett 27:4514-4519
Garg, Gaurav; Forsberg, Leah K; Zhao, Huiping et al. (2017) Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors. Chemistry 23:16574-16585
White, Peter T; Subramanian, Chitra; Zhu, Qing et al. (2016) Novel HSP90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion. Surgery 159:142-51

Showing the most recent 10 out of 46 publications